Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck

Silke Tribius, Stefanie Kronemann, Yasemin Kilic, Ursula Schroeder, Samer Hakim, Steven E. Schild, Dirk Rades

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background and Purpose:The optimal radiochemotherapy regimen for advanced head-and-neck cancer is still debated. This nonrandomized study compares two cisplatin-based radiochemotherapy regimens in 128 patients with locally advanced unresectable stage IV squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods:Concurrent chemotherapy consisted of either two courses cisplatin (20 mg/m2/d1-5 + 29-33; n = 54) or two courses cisplatin (20 mg/m2/d1-5 + 29-33) + 5-fluorouracil (5-FU; 600 mg/m 2/d1-5 + 29-33; n = 74). Results:At least one grade 3 toxicity occurred in 25 of 54 patients (46%) receiving cisplatin alone and in 52 of 74 patients (70%) receiving cisplatin + 5-FU. The latter regimen was particularly associated with increased rates of mucositis (p = 0.027) and acute skin toxicity (p = 0.001). Seven of 54 (13%) and 20 of 74 patients (27%) received only one chemotherapy course due to treatment-related acute toxicity. Late toxicity in terms of xerostomia, neck fibrosis, skin toxicity, and lymphedema was not significantly different. The 2-year locoregional control rates were 67% after cisplatin alone and 52% after cisplatin + 5-FU (p = 0.35). The metastases-free survival rates were 79% and 69%, respectively (p = 0.65), and the overall survival rates 70% and 51%, respectively (p = 0.10). On multivariate analysis, outcome was significantly associated with performance status, T-category, N-category, hemoglobin level prior to radiotherapy, and radiotherapy break > 1 week. Conclusion:Two courses of fractionated cisplatin (20 mg/m 2/day) alone appear preferable, as this regimen resulted in similar outcome and late toxicity as two courses of cisplatin + 5-FU, but in significantly less acute toxicity.

Original languageEnglish (US)
Pages (from-to)675-681
Number of pages7
JournalStrahlentherapie und Onkologie
Volume185
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Chemoradiotherapy
Fluorouracil
Cisplatin
Radiotherapy
Survival Rate
Carcinoma, squamous cell of head and neck
Drug Therapy
Xerostomia
Skin
Mucositis
Lymphedema
Head and Neck Neoplasms
Fibrosis
Neck
Multivariate Analysis
Neoplasm Metastasis

Keywords

  • Locally advanced head-and-neck cancer
  • Radiochemotherapy
  • Toxicity
  • Treatment outcome

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck. / Tribius, Silke; Kronemann, Stefanie; Kilic, Yasemin; Schroeder, Ursula; Hakim, Samer; Schild, Steven E.; Rades, Dirk.

In: Strahlentherapie und Onkologie, Vol. 185, No. 10, 10.2009, p. 675-681.

Research output: Contribution to journalArticle

Tribius, Silke ; Kronemann, Stefanie ; Kilic, Yasemin ; Schroeder, Ursula ; Hakim, Samer ; Schild, Steven E. ; Rades, Dirk. / Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck. In: Strahlentherapie und Onkologie. 2009 ; Vol. 185, No. 10. pp. 675-681.
@article{446e54a760694f3b93148d3a9e77ec5c,
title = "Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck",
abstract = "Background and Purpose:The optimal radiochemotherapy regimen for advanced head-and-neck cancer is still debated. This nonrandomized study compares two cisplatin-based radiochemotherapy regimens in 128 patients with locally advanced unresectable stage IV squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods:Concurrent chemotherapy consisted of either two courses cisplatin (20 mg/m2/d1-5 + 29-33; n = 54) or two courses cisplatin (20 mg/m2/d1-5 + 29-33) + 5-fluorouracil (5-FU; 600 mg/m 2/d1-5 + 29-33; n = 74). Results:At least one grade 3 toxicity occurred in 25 of 54 patients (46{\%}) receiving cisplatin alone and in 52 of 74 patients (70{\%}) receiving cisplatin + 5-FU. The latter regimen was particularly associated with increased rates of mucositis (p = 0.027) and acute skin toxicity (p = 0.001). Seven of 54 (13{\%}) and 20 of 74 patients (27{\%}) received only one chemotherapy course due to treatment-related acute toxicity. Late toxicity in terms of xerostomia, neck fibrosis, skin toxicity, and lymphedema was not significantly different. The 2-year locoregional control rates were 67{\%} after cisplatin alone and 52{\%} after cisplatin + 5-FU (p = 0.35). The metastases-free survival rates were 79{\%} and 69{\%}, respectively (p = 0.65), and the overall survival rates 70{\%} and 51{\%}, respectively (p = 0.10). On multivariate analysis, outcome was significantly associated with performance status, T-category, N-category, hemoglobin level prior to radiotherapy, and radiotherapy break > 1 week. Conclusion:Two courses of fractionated cisplatin (20 mg/m 2/day) alone appear preferable, as this regimen resulted in similar outcome and late toxicity as two courses of cisplatin + 5-FU, but in significantly less acute toxicity.",
keywords = "Locally advanced head-and-neck cancer, Radiochemotherapy, Toxicity, Treatment outcome",
author = "Silke Tribius and Stefanie Kronemann and Yasemin Kilic and Ursula Schroeder and Samer Hakim and Schild, {Steven E.} and Dirk Rades",
year = "2009",
month = "10",
doi = "10.1007/s00066-009-1992-x",
language = "English (US)",
volume = "185",
pages = "675--681",
journal = "Strahlentherapie und Onkologie : Organ der Deutschen R{\"o}ntgengesellschaft ... [et al]",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "10",

}

TY - JOUR

T1 - Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck

AU - Tribius, Silke

AU - Kronemann, Stefanie

AU - Kilic, Yasemin

AU - Schroeder, Ursula

AU - Hakim, Samer

AU - Schild, Steven E.

AU - Rades, Dirk

PY - 2009/10

Y1 - 2009/10

N2 - Background and Purpose:The optimal radiochemotherapy regimen for advanced head-and-neck cancer is still debated. This nonrandomized study compares two cisplatin-based radiochemotherapy regimens in 128 patients with locally advanced unresectable stage IV squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods:Concurrent chemotherapy consisted of either two courses cisplatin (20 mg/m2/d1-5 + 29-33; n = 54) or two courses cisplatin (20 mg/m2/d1-5 + 29-33) + 5-fluorouracil (5-FU; 600 mg/m 2/d1-5 + 29-33; n = 74). Results:At least one grade 3 toxicity occurred in 25 of 54 patients (46%) receiving cisplatin alone and in 52 of 74 patients (70%) receiving cisplatin + 5-FU. The latter regimen was particularly associated with increased rates of mucositis (p = 0.027) and acute skin toxicity (p = 0.001). Seven of 54 (13%) and 20 of 74 patients (27%) received only one chemotherapy course due to treatment-related acute toxicity. Late toxicity in terms of xerostomia, neck fibrosis, skin toxicity, and lymphedema was not significantly different. The 2-year locoregional control rates were 67% after cisplatin alone and 52% after cisplatin + 5-FU (p = 0.35). The metastases-free survival rates were 79% and 69%, respectively (p = 0.65), and the overall survival rates 70% and 51%, respectively (p = 0.10). On multivariate analysis, outcome was significantly associated with performance status, T-category, N-category, hemoglobin level prior to radiotherapy, and radiotherapy break > 1 week. Conclusion:Two courses of fractionated cisplatin (20 mg/m 2/day) alone appear preferable, as this regimen resulted in similar outcome and late toxicity as two courses of cisplatin + 5-FU, but in significantly less acute toxicity.

AB - Background and Purpose:The optimal radiochemotherapy regimen for advanced head-and-neck cancer is still debated. This nonrandomized study compares two cisplatin-based radiochemotherapy regimens in 128 patients with locally advanced unresectable stage IV squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods:Concurrent chemotherapy consisted of either two courses cisplatin (20 mg/m2/d1-5 + 29-33; n = 54) or two courses cisplatin (20 mg/m2/d1-5 + 29-33) + 5-fluorouracil (5-FU; 600 mg/m 2/d1-5 + 29-33; n = 74). Results:At least one grade 3 toxicity occurred in 25 of 54 patients (46%) receiving cisplatin alone and in 52 of 74 patients (70%) receiving cisplatin + 5-FU. The latter regimen was particularly associated with increased rates of mucositis (p = 0.027) and acute skin toxicity (p = 0.001). Seven of 54 (13%) and 20 of 74 patients (27%) received only one chemotherapy course due to treatment-related acute toxicity. Late toxicity in terms of xerostomia, neck fibrosis, skin toxicity, and lymphedema was not significantly different. The 2-year locoregional control rates were 67% after cisplatin alone and 52% after cisplatin + 5-FU (p = 0.35). The metastases-free survival rates were 79% and 69%, respectively (p = 0.65), and the overall survival rates 70% and 51%, respectively (p = 0.10). On multivariate analysis, outcome was significantly associated with performance status, T-category, N-category, hemoglobin level prior to radiotherapy, and radiotherapy break > 1 week. Conclusion:Two courses of fractionated cisplatin (20 mg/m 2/day) alone appear preferable, as this regimen resulted in similar outcome and late toxicity as two courses of cisplatin + 5-FU, but in significantly less acute toxicity.

KW - Locally advanced head-and-neck cancer

KW - Radiochemotherapy

KW - Toxicity

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=70349775910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349775910&partnerID=8YFLogxK

U2 - 10.1007/s00066-009-1992-x

DO - 10.1007/s00066-009-1992-x

M3 - Article

C2 - 19806333

AN - SCOPUS:70349775910

VL - 185

SP - 675

EP - 681

JO - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

JF - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

SN - 0179-7158

IS - 10

ER -